|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling and marketing expenses | |||||
| Research and development expenses | |||||
| General and administrative expenses (including allowance for doubtful accounts of RMB139,445,017 and RMB7,632,517 for the years ended December 31, 2023 and 2024, respectively, and a reversal of allowance of RMB5,870,581 for the year ended December 31, 2025) | |||||
| Total operating expenses | |||||
| Government grants | |||||
| Operating loss | |||||
| Interest expenses | |||||
| Interest income | |||||
| Investment income | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Foreign currency translation adjustment, net of nil income taxes | |||||
| Unrealized gain on available-for-sale securities, net income taxes of RMB3,080, nil and nil for the year 2023, 2024 and 2025, respectively | |||||
| Less: reclassification adjustment for gain on available-for-sale securities realized in net loss, net of RMB64,025, nil and nil income taxes for the year 2023, 2024 and 2025, respectively | |||||
| Comprehensive loss | |||||
| Net loss per ordinary share | |||||
| -Basic | |||||
| -Diluted | |||||
| Weighted average number of ordinary shares and ordinary shares equivalents outstanding used in computing net loss per ordinary share | |||||
| -Basic | |||||
| -Diluted |
Loading...